Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
The OCT team would like to thank you for making the 2013 launch event such a huge success.
In September this year close to 200 industry professionals attended our first Outsourcing in Clinical Trials Nordics event to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical challenges.
Covering a broad range of content related to all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques, this year’s agenda boasted presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty local to this industry hub.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within biotechnology, pharmaceutical, virtual and medical device companies throughout the Nordic region.
Outsourcing in Clinical Trials Nordics boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Israel-based Kamada has completed patient enrolment in its US Phase II/III clinical trial of KamRAB as a post-exposure prophylaxis (PEP) treatment for rabies.
Denmark-based biotechnology firm Genmab has announced that its partner, Janssen Biotech (Janssen) will initiate a Phase III trial of daratumumab for treatment of patients with relapsed or refractory multiple myeloma (MM).
US-based clinical stage biopharmaceutical firm Heat Biologics has dosed the first patient in its Phase I/II bladder cancer clinical trial of its investigational biologic product candidate, HS-410.
Belgium-based integrated biopharmaceutical firm ThromboGenics will soon start a US Phase IV trial with Jetrea (ocriplasmin) for the treatment of symptomatic vitreomacular adhesion (VMA)/ vitreomacular traction (VMT).
Boehringer Ingelheim has reported positive results from large-scale Phase III studies demonstrating that once-daily tiotropium delivered via the Respimat inhaler was effective and well-tolerated in patients across asthma severities.
US-based Conatus Pharmaceuticals has started a Phase II clinical study of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoh…